Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

What Are Novavax's Long-Term Prospects?

TheMotleyFool

0 0

Last year, Novavax (NASDAQ: NVAX) was one of the strongest stocks in the entire market. The micro cap ran up from $4 a share in January all the way to $119 in December. Then in 2021, the stock almost tripled after Novavax reported positive phase 3 data in its U.K. study for a COVID-19 vaccine. After hitting $330 a share, investors were whipsawed as the stock price dropped to $149.

Is Novavax stock a buy today? Corinne Cardina, the Bureau Chief for Healthcare and Cannabis at Fool.com, and Motley Fool contributor Taylor Carmichael discuss this vaccine specialist. This segment was recorded live on March 5.

Source Fool.com

Like: 0

NVAX

Share